Company Overview and News

Associated Banc-Corp (ASB) Beats on Q1 Earnings, Costs Rise

12h zacks
Associated Banc-Corp’s (ASB - Free Report) first-quarter 2018 adjusted earnings of 50 cents per share surpassed the Zacks Consensus Estimate of 41 cents. Also, the figure compares favorably with the prior-year quarter’s earnings of 35 cents. The reported quarter’s earnings excluded acquisition related costs in connection with the Bank Mutual deal. Results benefited primarily from an improvement in revenues and absence of provision for credit losses.
Upvote Downvote

Cached at Huntington: Lincoln's Last-Known Check - WSJ

2018-04-14 wsj
Peggy Draeger, a facilities employee at Huntington Bancshares Inc., didn't imagine her love of Abraham Lincoln would come into focus conducting inventory of bank vaults. But when employees found a long-forgotten box, Ms. Draeger sat on the floor and pulled out the last-known signature of the Great Emancipator—on a check.
Upvote Downvote

Wells Fargo (WFC) to Combine Corporate and Investment Banks

2018-04-06 zacks
With a view to trim costs and enhance the quality of customer service, Wells Fargo & Company (WFC - Free Report) is making plans to merge corporate and investment banks. The news was first reported by the Wall Street Journal.
Upvote Downvote

HBAN or TCF: Which Bank Stock Will Provide Better Returns?

2018-04-04 zacks
The U.S. banking sector has been the center of attraction for quite some time now due to the favorable turn of events since Trump took office. Moreover, continual rise in interest rates and lower commercial tax rate are likely to further boost profitability of the banks.
Upvote Downvote

Cramer Remix: Buy high-growth stocks during the sell-off

2018-03-22 cnbc
On the worst day for markets since Feb. 8, CNBC's Jim Cramer took callers' questions in a sell-off strategy session to help them navigate the madness.
Upvote Downvote

Cramer's lightning round: Cannabis stock GW Pharmaceuticals is too hot

2018-03-22 cnbc
GW Pharmaceuticals: "This is cannabinoid. Cannabis is very hot as a concept to invest in. I think the stock's had too big a run. I'm not recommending it anymore. It got up, we liked it a lot lower, that's all I have to say."
Upvote Downvote

TCF Financial started at neutral with $24 stock price target at UBS

2018-03-22 marketwatch
A probe by the Manhattan district attorney into Newsweek Media Group, including its ad practices and loans, has widened to look at ties to a California bible college.
Upvote Downvote

TCF Financial: A Potential Takeover Target?

2018-02-15 seekingalpha
More importantly, the bank increased its dividend by 100%, from $0.30 per share to $0.60 per share.
Upvote Downvote

Huntington Bancshares’ (HBAN) Upgraded to Hold at recent price of $15.1

2018-02-09 investorplace
Portfolio Grader currently ranks Huntington Bancshares Inc (NASDAQ:HBAN) a Hold. The approach to fundamental and quantitative metrics used in this analytical tool assesses and ranks nearly 5,000 stocks each week. The shares have been upgraded from a Sell to a Hold in the last week. The Hold recommendation, which was recently up graded from a Sell to Hold, for Huntington Bancshares Inc is the outcome of an analytical process that is proprietary which yielded conclusions that were above average in 4 areas: a ranking in its sector group that is in the top half, ranking in the company's industry group that is in the top third, a quantitative risk/reward calculation that is better than average and an analytical score that is above average; and produced below average results in 2 areas: an economic sector rated below average in attractiveness, and an industry group ranked below average in attractiveness.
Upvote Downvote

Associated Banc-Corp (ASB) Hikes Dividend: Should You Buy?

2018-02-07 zacks
Associated Banc-Corp (ASB - Free Report) announced a 7.1% hike in its quarterly cash dividend. The new dividend of 15 cents per share will be paid on Mar 15 to shareholders on record as of Mar 1. Based on yesterday’s closing price of $24.25 per share, the dividend yield is 2.47%. The hike comes after the company increased its dividend by 16.7% in October 2017. In fact, given a solid capital and liquidity position, the company is expected to continue enhancing shareholder value through efficient capital-deployment activities.
Upvote Downvote highlights: Advance Auto Parts, J.B. Hunt Transport Services, Arthur J. Gallagher, Huntington Bancshares and SS&C Technologies Holdings

2018-01-30 zacks
Chicago, IL – Jan 30, 2018 - Stocks in this week’s article include: Advance Auto Parts, Inc. (AAP - Free Report) , J.B. Hunt Transport Services, Inc. (JBHT - Free Report) , Arthur J. Gallagher & Co. (AJG - Free Report) , Huntington Bancshares Inc. (HBAN - Free Report) and SS&C Technologies Holdings, Inc. (SSNC - Free Report) .
Upvote Downvote

Bet on These 5 Top Stocks Displaying Attractive Sales Growth

2018-01-29 investorplace
Strong sales growth is one of the most important characteristics of potential winners in the stock market. The companies that put emphasis on sales management have a competitive advantage, as strong sales are generally converted into growth.
Upvote Downvote

Bet on These 5 Top Stocks Displaying Attractive Sales Growth

2018-01-29 zacks
Strong sales growth is one of the most important characteristics of potential winners in the stock market. The companies that put emphasis on sales management have a competitive advantage, as strong sales are generally converted into growth. Revenues are often more closely monitored than earnings while assessing the growth of a business. This is because investors want to make sure whether a business has the capability to generate more sales over time to cater to an expanding customer base.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 446150401